

## References

1. Arterialnaya Hypertensiya. Updated and adapted clinical guidelines based on evidence. Annex to the Order of Ministry of Health of Ukraine № 384 from 24.05.2012 "On the approval and implementation of medical and technical documents on standardization of medical care for hypertension (in Ukr).
2. Brytov AN, Bystrov NM. Resistant hypertension: current approaches to diagnosis and treatment. *Rat Pharmacother in Cardiol* 2007;2:38–42(in Ukr).
3. Svischenko EP. Hypertension and kidney disease. *Art Ther* 2005;4:20 (in Ukr).
4. Syrenko YM. Hypertension and concomitant diseases. Donetsk: Publishing House "Zaslavskiy".2010.p.383 (in Ukr).
5. Calhoun D, Jones D, Textor S. Resistant hypertension: diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional educational committee of the Council for high blood pressure research. *Hypertens* 2008;51;6:1403–19.
6. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment panel III criteria for the metabolic syndrome. *Diabetes* 2004;53:2087–97.
7. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. *Circulation* 2005;112:666–73.
8. Dijk JM, Graat G, Bots ML. Carotid intima-media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. *Eur Heart J* 2006;24:1971–8.
9. Donald Lloyd-Jones, Robert Adams, Mercedes Carnethon, Giovanni De Simone T. Heart Disease and Stroke Statistics 2009 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. *Circulation* 2009;119:21–181.
10. European guidelines on cardiovascular diseases prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular diseases prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2007;28:2375–414.
11. Hall JE, Brands MW, Henegar JR. Mechanisms of hypertension and kidney disease in obesity. *Ann NY Acad Sci* 1999;892:91–107.
12. Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 2009;120:1640–5.
13. Sharma AM, Padwal R, Sui X, Blair SN. Edmonton Obesity Staging System: association with weight history and mortality risk. *Appl Physiol Nutr Metab* 2011;36:570–6.
14. Matsumura, Ohtsubo T, Oniki H. Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension. *Circ J* 2006;70:885–8.
15. Montalcini T, Gorgo G, Gazzaruso C. Relation between serum uric acid and carotid intima-media thickness in healthy postmenopausal women. *Intern Emerg Med* 2007;2:19–23.

16. Verdecchia P, Schillaci G, Borgioni C. Prognostic significance of serial changes in left ventricular mass in essential hypertension. *Circulation* 1998;97:48–54.
17. Volpe M. Microalbuminuria Screening in Patients With Hypertension: Recommendations for Clinical Practice. *Int J Clin Pract* 2008;62 (1):97–108.
18. Wijk I, Kappelle LJ, van Gijn J; LiLAC study group (2005) Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. *Lancet* 365(9477):2098–104.